65,437 trials
Depressive Disorder · Pregnancy
Primary: Number of Participants in the Relapse-Prevention Group (Group 1) Experiencing a Major Depressive Episode Relapse — 3 Participants — p=0.005
Erosive Gastritis
Primary: Changes in Erosions — 4.36; 3.38; 2.32; 2.43 erosions
Food Allergy
Primary: Change in Allergen-specific Serum IgG4 and IgE — 578.5; 738.5 Total serum IgE (kU/L)
Resilience, Psychological
Primary: Number of Participants Completing Treatment Sessions — 4; 9 Participants
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Primary: Overall Survival (OS) — 9.7; 7.8 months — p=0.1800
Desmoid Fibromatosis
Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001
Arthroplasty, Replacement, Knee
Primary: Comparison of Maximum Passive and Active Flexion. — 124.58; 125.14; 126.64; 131.33 degree
Uterine Fibroids · Adhesions
Primary: Number of Participants With Absence of Newly Formed Intrauterine Adhesions Following RF Ablation of Fibroids — 34 Participants
Congenital Muscular Dystrophy
Primary: Pharmacokinetic Profile of Omigapil:Maximum Observed Plasma Concentration (Cmax) of Omigapil — 1.05; 4.75; 2.15; 3.27 ng/mL
Preeclampsia
Primary: Prevalence of Urine Congophilia Using Congo Red Test GV-005 — 87; 18 Participants
Colorectal Adenoma · Colorectal Polyp · Colon Cancer
Primary: Adenoma Detection Rates — 143; 124 Participants
Heartfailure
Primary: Phrenic Nerve Complication Free Rate — 99.5 % of participants — p=<0.0001
Fetal Monitoring
Primary: Fetal Heart Rate With the Laborview System Versus the CTG Monitor - Pilot Comparison Study — 5.282 beats per minute — p=<.1
Rhinitis, Allergic, Seasonal
Primary: Median Time to Onset of Nasal Symptom Relief as Assessed by Participant Diary Responses — 35.9; 72.0 Hours — p=<0.01
Stent Thrombosis
Primary: Very Late Stent Thrombosis — 92; 35 Participants